The Cancer Research Centre of Toulouse (CRCT)
Dr. Sylvie Giuriato
|
 |
|
Research Interest |
Dr Sylvie Giuriato has focused recently on the role of autophagy following crizotinib therapy in ALK-positive ALCL. The goal is to pursue understanding the role and the regulation (in particular post-transcriptional regulation through microRNAs and/or RNA-Binding proteins) of this process in different ALK-positive tumours, both in basal conditions and following targeted-, chemo- and immuno-therapies. |
Domenico Sorrentino
|
 |
|
Research Interest |
I received a master degree (MSc) in Pharmaceutical Biotechnology from University of Bologna and an Integrated master’s degree in Drug design and development from University of Pavia. I performed a traineeship in oncolytic virus field at DKFZ of Heidelberg. My professional interests focus on cancer research, particularly, on combinatorial treatments modulation. In addition, I will realize as PhD student for ALKATRAS consortium my next project that will concern the Role and regulation of autophagy in ALK dependent tumors. |
A wide array of deregulated miRNAs has previously been defined by a number of ERIA members in ALK-induced malignancies and has potential diagnostic utility. Since the miRNA targeted sequences and the RNA-BP binding sites are often close or overlapping, the question of cross-talk between these two RNA modulators will be investigated in terms of classical (proliferation, survival, invasion) and emerging (autophagy, ER Stress) mechanisms of tumorigenesis.
We specifically aim to: Investigate the regulation of autophagy signalling by miRNAs and RNA-BPs or epigenetic modifications; determine the role of autophagy, using classical autophagy assays, in ALCL, NSCLC and neuroblastoma cell lines and mouse models; test whether autophagy inhibition can potentiate the efficacy of ALK inhibition by Crizotinib and other second generation inhibitors.
Expected Results:
Identification of the regulatory network of autophagy in ALK+ malignancies; optimize current ALK therapies by interfering with autophagy-related pathways; develop of biomarkers to predict therapy response in ALK+ patients
Planned secondment(s):
Year 1: Sofigen (PO#10) – analysis of epigenetic modifications in ALCL – 1 month;
Year 2:Tuebingen (B#5)- analysis of miRNA and downstream signalling pathways – 2 months